# AfiniTRAC® ENROLLMENT FORM

AFINITOR®
(everolimus) tablets
2.5mg | 5mg | 15mg | 19mg

AfiniTRAC, P.O. Box 1476, San Bruno, CA 94066

Please complete the entire service request form and fax both pages to 1-877-705-2282.

Hours: Monday - Friday; 8 AM - 8 PM EST | Phone: 1-888-923-4648 | Fax: 1-877-705-2282 | Website: www.AFINITOR.com

### 1. PATIENT INFORMATION

Patient Name	Gender □ Male □ Female
Social Security Number	Date of Birth
Language Preference	
Legal Guardian Name (if applicable)	Relationship
Phone #	Alternate Phone #
Best Time to Call □ AM □ PM	E-mail Address
Address	
City	State ZIP
Patient Prescription Insur	rance Information
Please attach a copy of the front a	and back of the patient's insurance
card(s), if applicable.	
Insurance Name	
Policyholder Name	
Relationship to Patient	Policyholder DOB
Rx BIN/PCN #	
Group #	ID#
Pharmacy Services Phone # (back of co	ard)
Patient Medical Insurance	e Information
Fill in this section only if informa	tion differs from the Prescription
Insurance Information section abo	
Insurance Name	
Policyholder Name	
Relationship to Patient	Policyholder DOB
Insurance Phone #	
Group #	Policy/ID #
Rx BIN #	-
IVY DILA #	
Preferred Pharmacy Infor	mation
Pharmacy Name	
Phone #	Fax #
Address	

### 2. COMPLETE PRESCRIBER INFORMATION

Prescriber Name	Specialty	
Facility Name		
Address		
City	State	ZIP
Phone #	Fax #	
NPI #	Tax ID #	DEA/State License #
Office Contact Name		
Office Phone #	Office E-mail	

## 3. READ AND SIGN

#### PRESCRIBER SIGNATURES

I have read and agree to the Prescriber Consent (section 4) or (REQUIRED)	n page 2 of this document.
Prescriber Signature (no stamps)	Date
I have read and agree to the Prescription Information (section 7 I certify that I am the health care professional who has prescrib Tablets to the patient identified on this form. I authorize the No prescribing information to a third party(ies) to dispense AFINIT	7) on page 3 of this document. led AFINITOR® (everolimus) vartis Group to transmit
Prescriber Signature (no stamps)	Date Date
I have read and agree to the AFINITOR Free-Trial Support Progrethis document. I certify that this therapy is medically necessar is accurate to the best of my knowledge. (OPTIONAL)	
X	
Prescriber Signature (no stamps)	Date
I have read and agree to the Patient Assistance Program Conon page 2 of this document. <b>(OPTIONAL)</b>	sent for Physician (section 5)
X	
Prescriber Signature (no stamps)	Date

PATIENT SIGNATURES	
I have read and agree to the Patient Authorization (section 6) or (REQUIRED)	n page 2 of this document.
X	
Patient or Legal Guardian Signature	Date
I have read and agree to receive materials, promotions, and offe Patient Marketing Consent (section 9) on page 4 of this docume	
Patient or Legal Guardian Signature	Date
I have read and agree to the Patient Assistance Program Conser document. (OPTIONAL)	nt (section 10) on page 4 of this
X	
Patient or Legal Guardian Signature	Date

Please see accompanying full Prescribing Information.

City



State

ZIP

#### 4. PHYSICIAN AUTHORIZATION

I certify that I have provided the patient with materials that describe AfiniTRAC and have enrolled the patient in this program at the patient's request and that the patient agrees to be contacted by Program administrators.

# 5. PATIENT ASSISTANCE PROGRAM CONSENT FOR PHYSICIAN (TO BE SIGNED ONLY IF PATIENT IS APPLYING TO PATIENT ASSISTANCE PROGRAM [PAP])

My signature in Section 3 certifies that the person listed is my patient for whom I have prescribed the drug identified on the third page. I certify that any medications received from Novartis Pharmaceuticals Corporation, its affiliates, business partners and agents (together, the "Novartis Group") in connection with this application will be used only for the patient named on this form. These medications will not be offered for sale, trade, or barter. Additionally, no claim for reimbursement will be submitted concerning these medications to Medicare, Medicaid, or any third party, nor will any medications be returned for credit. I acknowledge that I have assisted the patient in enrolling in the Novartis PAP exclusively for purposes of patient care and not in consideration for, expectation of, or actual receipt of remuneration of any sort. I also agree that Novartis has the right to contact the patient directly to confirm receipt of medications, and I understand that Novartis may revise, change, or terminate this program at any time. Finally, to the best of my knowledge, the patient listed above meets Novartis' eligibility criteria for the PAP.

### 6. PATIENT AUTHORIZATION

I authorize my doctor(s) and their staff, my employer, my caretaker, and my health insurer(s) to disclose my personal information, including information about my insurance, prescriptions, medical condition, and health ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates, business partners, and agents (together, the "Novartis Group") so that the Novartis Group can (i) help to verify or coordinate insurance coverage or otherwise obtain payment for my treatment with AFINITOR® (everolimus) Tablets, (ii) coordinate my receipt of and payment for AFINITOR, (iii) facilitate the administration of AFINITOR to me, (iv) provide disease awareness and management programs and materials to me or my caretaker, (v) manage the AFINITOR Patient Support Program, and (vi) conduct market research, quality assurance, and other internal business activities. I authorize the Novartis Group to disclose my Personal Information to any pharmacies, insurance carriers, health care providers (including my doctor(s) and their staff), my caretaker, and other third parties for the purposes described above. I understand that these other parties may report back to the Novartis Group any Personal Information about me that they may create or receive and that the Novartis Group may disclose such Personal Information to my caretaker, to my doctor(s) and their staff and use it for the purposes described above. I authorize the Novartis Group to contact me or my caretaker directly for the purposes described above. I agree to receive AFINITOR Patient Support Program phone calls and mailing materials from the Novartis Group at the number(s) and address provided. I understand that my cell phone carrier's standard rates may apply for calls received at the numbers provided. I understand and agree that my pharmacy, health insurance company, and health care providers may receive remuneration from the Novartis Pharmaceuticals Corporation in exchange for disclosing my Personal Information to Novartis Pharmaceuticals Corporation and/or for providing me with therapy support services subsidized by Novartis Pharmaceuticals Corporation. I understand that once my health information is disclosed it may no longer be protected by federal or state law regarding patient privacy and that neither my doctor(s), nor my employer, nor my health insurer can guarantee that it will not be redisclosed to a third party. I understand that I may refuse to sign this authorization or revoke it at any time in the future, and my refusal or future revocation will not affect the commencement, continuation, or quality of my treatment by my doctor(s); however, if I revoke this authorization. I may no longer be eligible to participate in the AFINITOR Patient Support Program. I understand that this authorization will remain valid for 5 years after the date of my signature, unless I revoke it earlier by calling 1-888-923-4648. I also understand that the AFINITOR Patient Support Program may be changed or ended at any time without prior notification and that I may receive a copy of this authorization.

Rx: AFINITOR® (everolimus) Tablets for oral administration  Dosage strength (check one)  2.5 mg	Patient Height Patient Weight  BSA  Allergies  NKDA or List: Current Therapies/Medications  Therapeutic Equivalents If applicable, list prior patient medications and related information  Past Therapy Dates of Therapy  Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and other patient and polying for the patient
Rx: AFINITOR® (everolimus) Tablets for oral administration  Dosage strength (check one)  2.5 mg	Administer as oral suspension in water only.  Drink mg once daily. Dther
Dosage strength (check one)  2.5 mg	□ Drink mg once daily. □ Other
□ 2.5 mg □ 5 mg □ 10 mg  Other Dosing □ 10 mg  Dosing Instructions: Take □ Tablet(s) Once Per Day  Quantity □ # of Days Supplied □ Days  Refills Authorized □ Void After □ Days  Primary Diagnosis □ ICD-9 Code □ Secondary Diagnosis (if any) □ ICD-9 Code □   AFINITOR SUPPORT PROGRAMS Below, please find added to the process of the proces	Patient Height Patient Weight  BSA  Allergies  NKDA or List:
Other Dosing	BSA Allergies  NKDA or List: Current Therapies/Medications Therapeutic Equivalents If applicable, list prior patient medications and related information Past Therapy Dates of Therapy  Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and other patient  PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL) This step is not required if you are not applying for the patient
Other Dosing  Dosing Instructions: Take Tablet(s) Once Per Day  Quantity # of Days Supplied  Refills Authorized Void After Days  Primary Diagnosis ICD-9 Code  Secondary Diagnosis (if any) ICD-9 Code	Allergies NKDA or List:  Current Therapies/Medications  Therapeutic Equivalents If applicable, list prior patient medications and related information  Past Therapy  Dates of Therapy  Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and oth  PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL) This step is not required if you are not applying for the patient
Quantity# of Days Supplied  Refills Authorized Void After Days  Primary Diagnosis ICD-9 Code  Secondary Diagnosis (if any) ICD-9 Code  AFINITOR SUPPORT PROGRAMS Below, please find add	Allergies NKDA or List:  Current Therapies/Medications  Therapeutic Equivalents If applicable, list prior patient medications and related information  Past Therapy  Dates of Therapy  Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and oth  PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL) This step is not required if you are not applying for the patient
Quantity# of Days Supplied  Refills Authorized Void After Days  Primary Diagnosis ICD-9 Code  Secondary Diagnosis (if any) ICD-9 Code  AFINITOR SUPPORT PROGRAMS Below, please find add	Current Therapies/Medications  Therapeutic Equivalents If applicable, list prior patient medications and related information  Past Therapy  Dates of Therapy  Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and other patient programs are not applying for the patient
Refills Authorized	Therapeutic Equivalents If applicable, list prior patient medications and related information  Past Therapy  Dates of Therapy  Justification for Brand Name  Additional AFINITOR programs that are designed to offer financial support and other patient and prior the patient in th
Primary DiagnosisICD-9 Code  Secondary Diagnosis (if any)ICD-9 Code  AFINITOR SUPPORT PROGRAMS Below, please find ad	If applicable, list prior patient medications and related information  Past Therapy  Dates of Therapy  Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and oth  PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL) This step is not required if you are not applying for the patient
Secondary Diagnosis (if any)ICD-9 Code  AFINITOR SUPPORT PROGRAMS Below, please find ad	Past Therapy  Dates of Therapy  Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and oth  PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL)  This step is not required if you are not applying for the patient
AFINITOR SUPPORT PROGRAMS Below, please find ad	Justification for Brand Name  dditional AFINITOR programs that are designed to offer financial support and oth  PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL)  This step is not required if you are not applying for the patient
	dditional AFINITOR programs that are designed to offer financial support and oth  PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL) This step is not required if you are not applying for the patient
	PATIENT ASSISTANCE PROGRAM (PAP) (OPTIONAL) This step is not required if you are not applying for the patient
	This step is not required if you are not applying for the patient
AFINITOR 7-DAY FREE TRIAL PROGRAM (OPTIONAL)	
The AFINITOR 7-Day Free Trial Program provides patients with an	
introductory supply of AFINITOR. Eligible patients can receive an	assistance program. (For patient assistance consideration, please attach proof of income.)
introductory 7-day supply and continue to receive temporary	attach proof of income.)
support for up to 56 days OR until their coverage begins. This	Total number in household (including patient)
program is available to all patients without regard to purchase of AFINITOR or any other product.	
·	Number of adults contributing to household income
Dispensed directly from the AFINITOR® (everolimus) Tablets for oral	Are you a US resident? ☐ Yes ☐ No
administration or AFINITOR DISPERZ™ (everolimus tablets for oral	Are you a veteran of the US Armed Forces? ☐ Yes ☐ No
suspension) Support Program (at no cost to patient).	Have you received disability payments from Social Security for more than 24 months? □ Yes □ No
DISPENSE: 7-DAY SUPPLY REFILLS: 7	Do you have an application pending with Medicaid?
Dispense 1 AFINITOR® (everolimus) Tablets box	bo you have an approached politicing with medicals.
□ 2.5 mg □ 5 mg □ 7.5 mg □ 10 mg	Salary/Wages \$ Social Security \$
To be taken	
Dispense 1 AFINITOR DISPERZ™ box	Disability \$ Pension/Retirement \$
□ 2 mg □ 3 mg □ 5 mg	Alimony/Child support \$ Unemployment/Workman's comp \$
To be taken	Total household gross monthly income \$
	iotal nouseriolo gross monthly income \$
Starter product shipping address (check one)  If shipping address is the same as stated on page 1, you do not need to	Total household assets (exclude first home and car) \$
complete again.	
□ Prescriber Address □ Patient Address □ Other Address (below)	PRIOR AUTHORIZATION PROGRAM (OPTIONAL)
Phone #	<ol> <li>Is the requested medication:</li> <li>□ New</li> <li>□ Continuation of therapy</li> <li>□ Reauthorization</li> </ol>
Alternate Phone #	2) Has this patient had failure/intolerance to any other therapies for this diagnosis? If so, please list. OR please list therapeutic
Address	alternatives previously used with start/end dates and outcome:
	For additional space, please use back of form.
City State ZIP	
NOTE: New York state prescribers must submit a state-approved prescription with this completed form.	3) Length of therapy anticipated?
,	<ul><li>4) Is this therapy being used in combination with any other therapies?</li><li>□ Yes</li><li>□ No</li></ul>
Please see accompanying full Prescribing Information for	If so, please list

#### 9. PATIENT MARKETING CONSENT

I would also like to receive marketing information, offers, and promotions from Novartis Pharmaceuticals Corporation regarding its products, programs, and services. I understand that the Personal Information I supply to Novartis Pharmaceuticals will be shared with and among its business partners to provide me with Novartis-specific products, programs, services, and/or to conduct market research. I understand that Novartis Pharmaceuticals does not permit my Personal Information to be used by any of its business partners for their own separate marketing purposes. I agree to receive phone calls, e-mails, and mailed materials from Novartis Pharmaceuticals at the number(s) and address provided. I understand that my cell phone carrier's standard rates may apply for calls received at the numbers provided. I may cancel my participation at any time by calling 1-888-923-4648 and can find further information about Novartis Pharmaceuticals privacy practices in its privacy policy at www.pharma.us.novartis.com.

# 10. PATIENT ASSISTANCE PROGRAM CONSENT FOR PATIENT (TO BE SIGNED ONLY IF APPLYING TO PAP)

I give permission for my doctor(s) and their staff to disclose my personal information, including information about my insurance, prescription, medical condition, and health ("Health Information") to the Novartis Patient Assistance Foundation, Inc. (the "Foundation") so that the Foundation can decide if I am eligible for the Novartis Patient Assistance Program ("PAP"); operate the PAP and the Foundation; send me information about PAP and other programs that might help me pay for my medicines; send my information to other programs that might help me pay for my medicines; ask me for financial, insurance, and/or medical information, and share my information as required or permitted by law. I give permission to the Foundation to use information on this Application and any other information I give to the Foundation for these same reasons. I also give the Foundation permission to share my Health Information and other information with people and companies that work with the Foundation: government agencies, including the Centers for Medicare and Medicaid Services; insurance companies, including Medicare Part D plans; my doctor(s) and other people, or institutions who are involved in my health care, such as pharmacies and hospitals; other organizations that might help me pay for my medication. I promise that any information, including financial and insurance information that I provide to the Foundation, is complete and true and unless I have said something different in this application, I have no drug insurance coverage, which includes Medicaid, Medicare, or any public or private assistance programs or other form of insurance. If my income or health coverage changes, I will call the PAP at 1-800-277-2254. I know that the Foundation may change or end the PAP at any time. I know that if I do not sign this form, I will not be able to participate in the PAP, but this will not affect my ability to get medical care, seek payment for this care, or affect my enrollment or eligibility for insurance. I know that I can cancel this





Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080

1/14